• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
      • Creating value for start-ups
      • The IP driven start-up
    • Financial Services
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • Articles
    • News
    • Events
    • Resources
    • Unified Patent Court hub
    • Beyond Brexit: European trade mark hub
    • M&C Reacts
  • Contact Us
Marks & Clerk logo
Marks & Clerk logo
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
    • Creating value for start-ups
    • The IP driven start-up
  • Financial Services
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • Articles
  • News
  • Events
  • Resources
  • Unified Patent Court hub
  • Beyond Brexit: European trade mark hub
  • M&C Reacts
Photo: Mike Gilbert

Mike Gilbert

Partner

Europe
London

Get in contact

+44 20 7420 0250 mgilbert@marks-clerk.com
vCard

Mike is an IP lawyer who advises clients in a wide variety of business sectors on issues including litigation and dispute resolution, IP strategy and risk limitation, due diligence projects and commercial and licensing transactions involving IP. His primary focus and expertise, however, lies in life sciences patent litigation where he is considered to be one of the UK’s leading practitioners.

He has represented some of the world’s leading biopharmaceutical corporations in complex patent and technical disputes including Genentech, Roche, AstraZeneca, MedImmune, Daiichi Sankyo, Pfizer, AbbVie and Chugai to name but a few. He regularly advises those clients on SPC and paediatric extension matters, a field in which he is considered to be a particular expert. He has been responsible for some of the most important life sciences patent cases with a special focus on biotech and antibody and large molecule cases.  He regularly advises on data and marketing exclusivity matters and orphan drug designations.

Within patent litigation, Mike has acted for and advised clients in actions in the Patents Court of the High Court, the Court of Appeal and on several petitions to the Supreme Court. He has also acted for SME client in their disputes in IPEC. Mike has significant experience of acting for clients involved in multi-jurisdictional technical disputes working as part of and coordinating integrated teams of IP specialists spanning many countries. He is actively involved in defending patent, SPC and data and marketing exclusivity rights around Europe for his clients.

Mike is well known for his strategic and creative vision and is consistently recommended in the IAM Patent 1000 guide, which describes him as “always at the top of the pile, especially for pharmaceutical matters”: “personable, approachable and user-friendly, he is a tenacious litigator able to take an objective view of a case at all times.” He is listed as a ‘patent leader’ by World IP Review and as an ‘IP Star' by Managing Intellectual Property. Mike is also listed by Legal 500, and recognised as an expert by Who’s Who Legal, which describe him as an “outstanding patent litigator” and say that his “glittering biotechnology practice wins him a position in the gold tier”. He is also recognised as the number one European thought leader by Who’s Who Life Sciences 2018, who describe Mike as follows:- “the “outstanding” Mike Gilbert ranks among the very elite of practitioners in our research, and is widely considered the “go-to practitioner for SPC matters in the life sciences sector".

Mike became a partner of the firm in 2001. He speaks French and Dutch and his interests include skiing, windsurfing, music and his family.

Example Cases

Aontec v Smartrac

Affymetrix v Illumina

Tercica v Insmed

MSD v Wyeth

MSD v Pfizer

GSK v Wyeth

Regeneron and Teva v Rinat

MedImmune v Celltech

MedImmune v Novartis

Genentech v Hospira

Lilly v Genentech

Regenernon and Bayer v Genentech

Takeda v Roche

UCB v Chugai

Astex v AstraZeneca

Whitserve v CPA

Jeyes v Henkel

Daiichi Sankyo v KRKA and TAD Pharma

Novamedix v Fox & Gardner

Languages

  • Français (French)
  • English
  • Nederlands (Dutch)

Specialist in

  • Litigation & Dispute Resolution
  • Due diligence
  • Commercial IP & Contracts
  • Freedom to Operate
  • EPO Patent Oppositions
  • Life Sciences
  • Chemistry
  • Medical Technologies

Qualifications

Diploma in Intellectual Property Law, Bristol University (1995)

Qualified as a Solicitor in England & Wales (1993)

Diploma in Law, Cambridge University (1990)

BA (Hons) Natural Sciences, Cambridge University (1989)

Search our people

Latest Insights

Chemistry
Article
- 24 March 2023

Preliminary position on priority published

As we reported in early 2022, the Enlarged Board of Appeal of the EPO are considering two pending referrals (G1/22 and G2/22) regarding the question of entitlement to priority. A hearing has now been set for 26 May 2023, and the Enlarged Board have now issued a preliminary opinion setting out the points to be discussed.
Read more
Quantum computing
Article
- 22 March 2023

International patent insights on quantum computing

The latest patent insight report from the European Patent Office (EPO) looks at the trends in patent filings for quantum computing, and has uncovered some interesting findings.
Read more
Article
- 22 March 2023

InterDigital v Lenovo: The latest FRAND judgment

On 16 March 2023, Mr Justice Mellor handed down the latest FRAND judgment: InterDigital v Lenovo. The case concerned a dispute between InterDigital and Lenovo as to the terms on which Lenovo should take a licence to InterDigital’s portfolio of patents which had been declared essential to the European Telecommunications Standard Institute (ETSI) Standards.
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Press Enquiries
  • Lexology
  • Mondaq